- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01283100
A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
22 dicembre 2014 aggiornato da: ViiV Healthcare
A Phase 1, Open Label, Single Sequence, Two-Way Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1379572 Pharmacokinetics in Healthy Adult Subjects
This is a single-center, open-label, three-period, fixed-sequence cross over study in healthy adult subjects.
A total of approximately 16 healthy subjects will be enrolled to provide data from 12 evaluable subjects.
Subjects will have a screening visit within 30 days prior to the first dose of study drug, three treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
There will be a washout period between Period 1 and Period 2 but no washout between Period 2 and Period 3. Day 1 of Period 3 will be the day after Day 5 of Period 2.
Panoramica dello studio
Stato
Ritirato
Intervento / Trattamento
Descrizione dettagliata
ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship
Tipo di studio
Interventistico
Fase
- Fase 1
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
New York
-
Buffalo, New York, Stati Uniti, 14202
- GSK Investigational Site
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 18 anni a 55 anni (Adulto)
Accetta volontari sani
Sì
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, vital signs, laboratory tests, and electrocardiograms (ECGs).
- A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- Male or female between 18 and 55 years of age inclusive, at the time of signing the informed consent.
- A female subject is eligible to participate if she is of non-childbearing potential (i.e., physiologically incapable of becoming pregnant) including any female who: Is pre-menopausal with a documented bilateral tubal ligation, bilateral oophorectomy (removal of the ovaries) or hysterectomy, or is post-menopausal defined as 12 months of spontaneous amenorrhea. A follicle stimulating hormone (FSH) level will be performed to confirm a post-menopausal status. For this study, FSH levels > 40 MlU/ml is confirmatory.
- Male subjects must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until the follow-up visit.
- Body weight less than or equal to 50 kg for men and less than or equal to 45 kg for women and body mass index (BMI) within the range 18.5-31.0 kg/m2 (inclusive).
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
Exclusion Criteria:
- As a result of the medical interview, physical examination, or screening investigations, the Investigator considers the subject unfit for the study.
- The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
- Unwilling to refrain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study.
- History of regular alcohol consumption within 6 months of the study.
- Unwilling to abstain from alcohol for 48 hours prior to the start of dosing until collection of the final pharmacokinetic sample during each treatment period.
- History or regular use of tobacco- or nicotine-containing products within 3 months prior to screening.
- History/evidence of symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PCTA) or any clinically significant cardiac disease.
History/evidence of clinically significant pulmonary disease.
- History/evidence of pancreatitis.
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs. Subjects with a history of cholecystectomy should be excluded.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation. In addition, if heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
Note: this does not include plasma donation.
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- A positive test for HIV antibody.
- AST, ALT, alkaline phosphatase and bilirubin greater than or equal to 1.5xULN (isolated bilirubin >1.5x upper limit of normal (ULN) is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- Pregnant females as determined by positive serum pregnancy test at screening or prior to dosing.
- Lactating females.
- The subject's systolic blood pressure is outside the range of 90-140 miligrams of mercury (mmHg), or diastolic blood pressure is outside the range of 45-90 mmHg or heart rate is outside the range of 50-100 beats per minute (bpm) for female subjects or 45-100 bpm for male subjects at Screening and predose Day 1.
- Cardiac conduction abnormalities denoted by any of the following on a single 12-lead ECG at screening or predose Day 1 (a single repeat is allowed for eligibility determination).
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Treatment A
GSK1349572 50mg q24h x 7 days
|
50mg once every 24 hours for 7 days
|
Sperimentale: Treatment B
GSK2248761 200mg q24h x 7 days
|
200 mg once every 24 hours for 7 days
|
Sperimentale: Treatment C
GSK1349572 50mg q24h x 7 days + GSK2248761 200mg q24h x 7 days
|
50mg once every 24 hours for 7 days
200 mg once every 24 hours for 7 days
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Plasma GSK1349572 steady state area under the curve (AUC) 0-tau following 50 mg q24h administration with and without GSK2248761 200 mg q24h
Lasso di tempo: 21 days
|
21 days
|
Plasma GSK1349572 steady state maximum observed concentration (Cmax) following 50 mg q24h administration with and without GSK2248761 200 mg q24h
Lasso di tempo: 21 days
|
21 days
|
Plasma GSK1349572 steady state Pre-dose trough concentration at the end of the dosing interval (Ctau) following 50 mg q24h administration with and without GSK2248761 200 mg q24h
Lasso di tempo: 21 days
|
21 days
|
Plasma GSK1349572 steady state predose concentration (C0) following 50 mg q24h administration with and without GSK2248761 200 mg q24h
Lasso di tempo: 21 days
|
21 days
|
Plasma GSK1349572 steady state minimum concentration (Cmin) following 50 mg q24h administration with and without GSK2248761 200 mg q24h
Lasso di tempo: 21 days
|
21 days
|
Plasma GSK2248761 steady state steady state AUC 0-tau following 200 mg q24h administration with and without GSK1349572 50 mg q24h
Lasso di tempo: 21 days
|
21 days
|
Plasma GSK2248761 steady state Cmax following 200 mg q24h administration with and without GSK1349572 50 mg q24h
Lasso di tempo: 21 days
|
21 days
|
Plasma GSK2248761 steady state Ctau following 200 mg q24h administration with and without GSK1349572 50 mg q24h
Lasso di tempo: 21 days
|
21 days
|
Plasma GSK2248761 steady state Cmin following 200 mg q24h administration with and without GSK1349572 50 mg q24h
Lasso di tempo: 21 days
|
21 days
|
Plasma GSK2248761 steady state C0 following 200 mg q24h administration with and without GSK1349572 50 mg q24h
Lasso di tempo: 21 days
|
21 days
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Safety and tolerability parameters, including the number of subjects with adverse events
Lasso di tempo: approximately 42 days
|
approximately 42 days
|
Safety and tolerability parameters, including the number of subjects receiving concurrent medications
Lasso di tempo: approximately 42 days
|
approximately 42 days
|
Safety and tolerability parameters, including change from baseline for clinical laboratory safety assessments
Lasso di tempo: approximately 42 days
|
approximately 42 days
|
Safety and tolerability parameters, including change from baseline for electrocardiogram (ECG) assessments
Lasso di tempo: approximately 42 days
|
approximately 42 days
|
Safety and tolerability parameters, including change from baseline for vital sign (blood pressure and heart rate) assessments
Lasso di tempo: approximately 42 days
|
approximately 42 days
|
GSK1349572 PK parameters including time of occurrence of maximum concentration (tmax) following administration of GSK1349572 50 mg q24h with and without co-administration of GSK2248761 200 mg q24h (Day 7 in Period 1, Period 3)
Lasso di tempo: approximately 28 days
|
approximately 28 days
|
GSK1349572 PK parameters including time of occurrence of minimum concentration (Tmin) following administration of GSK1349572 50 mg q24h with and without co-administration of GSK2248761 200 mg q24h (Day 7 in Period 1, Period 3)
Lasso di tempo: 21 days
|
21 days
|
GSK1349572 PK parameters including apparent clearance following oral dosing (CL/F) of GSK1349572 50 mg q24h with and without co-administration of GSK2248761 200 mg q24h (Day 7 in Period 1, Period 3)
Lasso di tempo: 21 days
|
21 days
|
GSK1349572 PK parameters including terminal half life (t½) following administration of GSK1349572 50 mg q24h with and without co-administration of GSK2248761 200 mg q24h (Day 7 in Period 1, Period 3)
Lasso di tempo: 21 days
|
21 days
|
GSK2248761 PK parameters tmax following administration of GSK2248761 200 mg q24h with and without co-administration of GSK1349572 50 mg q24h (Day 7 in Period 2 and Day 7 in Period 3)
Lasso di tempo: 21 days
|
21 days
|
GSK2248761 PK parameters tmin following administration of GSK2248761 200 mg q24h with and without co-administration of GSK1349572 50 mg q24h (Day 7 in Period 2 and Day 7 in Period 3).
Lasso di tempo: 21 days
|
21 days
|
GSK2248761 PK parameters CL/F following administration of GSK2248761 200 mg q24h with and without co-administration of GSK1349572 50 mg q24h (Day 7 in Period 2 and Day 7 in Period 3).
Lasso di tempo: 21 days
|
21 days
|
GSK2248761 PK parameters t½ following administration of GSK2248761 200 mg q24h with and without co-administration of GSK1349572 50 mg q24h (Day 7 in Period 2 and Day 7 in Period 3).
Lasso di tempo: 21 days
|
21 days
|
GSK1349572 and GSK2248761 Ctau values on Days 4-7 for each Period
Lasso di tempo: 21 days
|
21 days
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Collaboratori
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 marzo 2011
Completamento primario (Effettivo)
1 marzo 2011
Completamento dello studio (Anticipato)
1 giugno 2011
Date di iscrizione allo studio
Primo inviato
6 gennaio 2011
Primo inviato che soddisfa i criteri di controllo qualità
22 gennaio 2011
Primo Inserito (Stima)
25 gennaio 2011
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
24 dicembre 2014
Ultimo aggiornamento inviato che soddisfa i criteri QC
22 dicembre 2014
Ultimo verificato
1 dicembre 2014
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Infezioni da virus a RNA
- Malattie virali
- Infezioni
- Infezioni a trasmissione ematica
- Malattie trasmissibili
- Malattie sessualmente trasmissibili, virali
- Malattie trasmesse sessualmente
- Infezioni da lentivirus
- Infezioni da retroviridae
- Sindromi da deficit immunologico
- Malattie del sistema immunitario
- Malattie da virus lenti
- Infezioni da HIV
- Sindrome da immunodeficienza acquisita
- Meccanismi molecolari dell'azione farmacologica
- Agenti antinfettivi
- Agenti antivirali
- Inibitori enzimatici
- Agenti anti-HIV
- Agenti antiretrovirali
- Inibitori dell'integrasi dell'HIV
- Inibitori dell'integrasi
- Dolutegravir
Altri numeri di identificazione dello studio
- 114122
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su GSK1349572
-
GlaxoSmithKlineShionogiCompletato
-
ViiV HealthcareGlaxoSmithKlineCompletatoInfezione, virus dell'immunodeficienza umanaStati Uniti
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletatoInfezioni da HIV | Infezione, virus dell'immunodeficienza umanaStati Uniti
-
Merck Sharp & Dohme LLCReclutamentoMalattia di Von Hippel-Lindau | Tumore neuroendocrino pancreatico | Feocromocitoma/Paraganglioma | Tumore stromale gastrointestinale avanzato | Tumori mutati HIF-2αCanada, Stati Uniti, Danimarca, Francia, Germania, Ungheria, Italia, Federazione Russa, Spagna, Svezia, Tacchino, Israele, Regno Unito, Olanda, Australia, Cina, Singapore, Giappone
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletatoInfezioni da HIV | Infezione, virus dell'immunodeficienza umanaStati Uniti, Francia, Olanda, Spagna, Taiwan, Australia, Belgio, Federazione Russa, Canada, Regno Unito, Messico, Italia, Sud Africa, Romania, Argentina, Ungheria, Polonia, Chile, Grecia, Brasile
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletatoInfezione, virus dell'immunodeficienza umana IGermania, Spagna, Francia, Australia, Stati Uniti, Canada, Regno Unito, Italia, Federazione Russa
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletato
-
GlaxoSmithKlineShionogiCompletato
-
GlaxoSmithKlineShionogiCompletato
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletatoInfezioni da HIV | Soggetti sani | Insufficienza epatica | Infezione, virus dell'immunodeficienza umanaStati Uniti